Printed from https://ideas.repec.org/s/spr/pharme7.html
Content
December 2014, Volume 32, Issue 12
- 1201-1212 A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments
by Andrew Messali & Reginald Villacorta & Joel Hay - 1213-1229 The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
by Erika Wissinger & Ingolf Griebsch & Juliane Lungershausen & Michael Byrnes & Karin Travers & Chris Pashos - 1231-1243 Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer
by Steven Alberts & Tiffany Yu & Robert Behrens & Lindsay Renfro & Geetika Srivastava & Gamini Soori & Shaker Dakhil & Rex Mowat & John Kuebler & George Kim & Miroslaw Mazurczak & John Hornberger - 1245-1246 Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
by Afschin Gandjour - 1247-1247 Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
by A. Newall & M. Jit & R. Hutubessy - 1249-1250 Objectivity and Equity: Clarity Required. A Response to Hill and Olson
by Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe
November 2014, Volume 32, Issue 11
- 1035-1037 Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?
by Surrey Walton & Glen Schumock - 1039-1041 NICE, Social Values, and Balancing Objectivity and Equity
by Suzanne Hill & Leslie Olson - 1043-1053 Some Inconsistencies in NICE’s Consideration of Social Values
by Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe - 1055-1061 Through a Glass Darkly: Economics and Personalised Medicine
by Alan Haycox & Munir Pirmohamed & Claire McLeod & Rachel Houten & Sarah Richards - 1063-1078 Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome
by Fotini Gialama & Evangelia Miloni & Nikos Maniadakis - 1079-1091 Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
by Patrick Zueger & Neil Schultz & Todd Lee - 1093-1104 The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
by Christina Yeung & Tuan Dinh & Joseph Lee - 1105-1114 A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
by Bijal Patel & Patricia Audet - 1115-1127 Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment
by Peter Ghijben & Emily Lancsar & Silva Zavarsek - 1129-1139 Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
by Shien Guo & Denis Getsios & Nikhil Revankar & Peng Xu & Gwilym Thompson & Joel Bobula & Loretto Lacey & Maren Gaudig - 1141-1145 The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees
by Manuel Arias & Francisco Díez
October 2014, Volume 32, Issue 10
- 937-942 Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary
by Robin Gauld - 943-950 Decision-Analytic Models: Current Methodological Challenges
by J. Caro & Jörgen Möller - 951-965 Reconceptualising the External Validity of Discrete Choice Experiments
by Emily Lancsar & Joffre Swait - 967-979 Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models
by Paul Tappenden & James Chilcott - 981-993 Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility
by Kevin Marsh & Peng Xu & Panagiotis Orfanos & James Gordon & Ingolf Griebsch - 995-1004 Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes
by Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi - 1005-1013 Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer
by David Lairson & Rohan Parikh & Janice Cormier & Wenyaw Chan & Xianglin Du - 1015-1028 Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis
by An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens - 1029-1029 Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
by Matt Stevenson & Peter Selby - 1031-1033 Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary”
by Scott Metcalfe & Rachel Grocott & Dilky Rasiah
September 2014, Volume 32, Issue 9
- 815-817 Hospital-Based Health Technology Assessment: Insights from New Zealand
by Stephen Munn - 819-824 Hospital-Based Health Technology Assessment: Developments to Date
by Marie-Pierre Gagnon - 825-839 HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes
by Véronique Raimond & Jean-Michel Josselin & Lise Rochaix - 841-851 The Burden of Disease in Rheumatoid Arthritis
by Till Uhlig & Rikke Moe & Tore Kvien - 853-864 Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
by Kevin Marsh & Peng Xu & Panagiotis Orfanos & Agnes Benedict & Kamal Desai & Ingolf Griebsch - 865-882 The Economic Burden of Head and Neck Cancer: A Systematic Literature Review
by Erika Wissinger & Ingolf Griebsch & Juliane Lungershausen & Talia Foster & Chris Pashos - 883-902 Discrete Choice Experiments in Health Economics: A Review of the Literature
by Michael Clark & Domino Determann & Stavros Petrou & Domenico Moro & Esther Bekker-Grob - 903-917 Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada
by Anita Brogan & Erik Smets & Josephine Mauskopf & Sarah Manuel & Ines Adriaenssen - 919-936 Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
by Antonio Gómez-Outes & Cristina Avendaño-Solá & Ana Terleira-Fernández & Emilio Vargas-Castrillón
August 2014, Volume 32, Issue 8
- 725-727 Transparency in Reimbursement Decisions: In Whose Best Interest?
by Tania Stafinski & Devidas Menon - 729-733 Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?
by James Chambers - 735-743 Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
by Matt Stevenson & Peter Selby - 745-758 Economic Evaluations of Gastroesophageal Reflux Disease Medical Management
by Andrew Gawron & Dustin French & John Pandolfino & Colin Howden - 759-773 A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis
by Ayse Kuspinar & Nancy Mayo - 775-787 Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
by Alex Diamantopoulos & A. Finckh & T. Huizinga & D. Sungher & L. Sawyer & D. Neto & F. Dejonckheere - 789-799 The Better than Dead Method: Feasibility and Interpretation of a Valuation Study
by R. Hoorn & A. Donders & M. Oppe & P. Stalmeier - 801-813 A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding
by Rosarin Sruamsiri & Piyameth Dilokthornsakul & Chayanin Pratoomsoot & Nathorn Chaiyakunapruk
July 2014, Volume 32, Issue 7
- 613-615 NICE’s Cost-Effectiveness Range: Should it be Lowered?
by J. Raftery - 617-626 Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs
by R. Diel & N. Lampenius - 627-637 Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease
by Laura Burgers & William Redekop & Johan Severens - 639-650 A Review of the Economics of Treating Clostridium difficile Infection
by Kari Mergenhagen & Amy Wojciechowski & Joseph Paladino - 651-680 Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review
by Fabrice Smieliauskas & Chun-Ru Chien & Chan Shen & Daniel Geynisman & Ya-Chen Shih - 681-691 Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
by Pieter Dylst & Arnold Vulto & Steven Simoens - 693-706 Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales
by Kamran Khan & Stavros Petrou & Oliver Rivero-Arias & Stephen Walters & Spencer Boyle - 707-724 Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
by Rachel Webber-Foster & Giorgi Kvizhinadze & Gareth Rivalland & Tony Blakely
June 2014, Volume 32, Issue 6
- 521-523 Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?
by Josephine Mauskopf - 525-531 Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
by A. Newall & M. Jit & R. Hutubessy - 533-546 Methods for Adjusting for Bias Due to Crossover in Oncology Trials
by K. Ishak & Irina Proskorovsky & Beata Korytowsky & Rickard Sandin & Sandrine Faivre & Juan Valle - 547-558 When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
by Jonathan Karnon & Hossein Haji Ali Afzali - 559-572 Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
by Shien Guo & Christopher Pelligra & Catherine Saint-Laurent Thibault & Luis Hernandez & Anuraag Kansal - 573-590 Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)
by Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery - 591-599 Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
by Klazien Matter-Walstra & Dirk Klingbiel & Thomas Szucs & Bernhard Pestalozzi & Matthias Schwenkglenks - 601-612 Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
by Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp
May 2014, Volume 32, Issue 5
- 425-427 Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now
by Wei Zhang & Aslam Anis - 429-442 How to Select the Right Cost-Effectiveness Model?
by H. Haalen & J. Severens & A. Tran-Duy & A. Boonen - 443-455 Is Individualized Medicine More Cost-Effective? A Systematic Review
by Maximilian Hatz & Katharina Schremser & Wolf Rogowski - 457-466 Fibromyalgia: Disease Synopsis, Medication Cost Effectiveness and Economic Burden
by Tracy Skaer - 467-478 Cost and Cost Effectiveness of Vaginal Progesterone Gel in Reducing Preterm Birth: An Economic Analysis of the PREGNANT Trial
by Laura Pizzi & Neil Seligman & Jason Baxter & Eric Jutkowitz & Vincenzo Berghella - 479-493 Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
by Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere - 495-507 Valuation of EQ-5D-3L Health States in Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health States
by Nan Luo & Pei Wang & Julian Thumboo & Yee-Wei Lim & Hubertus Vrijhoef - 509-520 A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
by Michael Drummond & Gerard Pouvourville & Elizabeth Jones & Jennifer Haig & Grece Saba & Hélène Cawston
April 2014, Volume 32, Issue 4
- 315-318 Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?
by Mike Paulden & Christopher McCabe & Jonathan Karnon - 319-325 Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room
by Simon Eckermann & Brita Pekarsky - 327-334 Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin
by Roberta Longo & Paul Baxter & Peter Hall & Jenny Hewison & Mehran Afshar & Geoff Hall & Christopher McCabe - 335-344 How to Estimate Productivity Costs in Economic Evaluations
by Marieke Krol & Werner Brouwer - 345-365 Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature
by Kevin Marsh & Tereza Lanitis & David Neasham & Panagiotis Orfanos & Jaime Caro - 367-375 Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010
by Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen - 377-393 A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk - 395-409 Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines
by Josephine Mauskopf & Miny Samuel & Doreen McBride & Usha Mallya & Steven Feldman - 411-419 Differential Time Preferences for Money and Quality of Life
by M. Parouty & H. Le & D. Krooshof & M. Postma - 421-422 Response to Letter to Editor: Capturing Disutility from Waiting Time
by Victoria Brennan & Simon Dixon - 423-424 Capturing Disutility from Waiting Time
by Afschin Gandjour
March 2014, Volume 32, Issue 3
- 231-234 The Role of Health Economics and Outcomes Research in Health Care Reform in China
by Wannian Liang & Jipan Xie & Hongpeng Fu & Eric Wu - 235-243 Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer
by Tan Chongqing & Peng Liubao & Zeng Xiaohui & Li Jianhe & Wan Xiaomin & Chen Gannong & Wang Siying & Ouyang Lihui & Zhao Ziying - 245-255 Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program
by Mingsheng Chen & Lijie Wang & Wen Chen & Luying Zhang & Hongli Jiang & Wenhui Mao - 257-264 Time Trends and Determinants of Pharmaceutical Expenditure in China (1990–2009)
by Lizheng Shi & Heidi Yang & Gang Cheng & Qingyue Meng - 265-275 Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China
by Suwei Yuan & Yan Liu & Na Li & Yunting Zhang & Zhe Zhang & Jingjing Tao & Lizheng Shi & Hude Quan & Mingshan Lu & Jin Ma - 277-292 The Impact of the Urban Resident Basic Medical Insurance on Health Services Utilisation in China
by Gang Chen & Gordon Liu & Fei Xu - 293-303 Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals
by Jing Wu & Judy Xu & Gordon Liu & Jiuhong Wu - 305-313 Treatment, Monitoring, and Economic Outcomes of Venous Thromboembolism Among Hospitalized Patients in China
by Eric Wu & Jipan Xie & Chun Wu & Ella Du & Nanxin Li & Ruoding Tan & Yuanli Liu
February 2014, Volume 32, Issue 2
- 101-108 Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial
by Vakaramoko Diaby & Georges Adunlin & Alberto Montero - 109-134 Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models
by Eleanor Heather & Katherine Payne & Mark Harrison & Deborah Symmons - 135-147 Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer
by Malek Hannouf & Bin Xie & Muriel Brackstone & Gregory Zaric - 149-157 Clinical and Economic Impact of Substituting Dexmedetomidine for Propofol due to a US Drug Shortage: Examination of Coronary Artery Bypass Graft Patients at an Urban Medical Centre
by Brandi Thoma & Julius Li & Cara McDaniel & Cindy Wordell & Nicholas Cavarocchi & Laura Pizzi - 159-172 The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis
by Paul Tappenden & Sue Harnan & Lesley Uttley & Matthew Mildred & Martin Walshaw & Christopher Taylor & Keith Brownlee - 173-191 The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer
by J. Jayasekera & E. Onukwugha & K. Bikov & C. Mullins & B. Seal & A. Hussain - 193-207 Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse
by Michael Adena & Jennifer Houltram & Stephen Mulligan & Carlene Todd & Grace Malanos - 209-223 Eliciting Preferences to Inform Patient-Centred Policies: the Case of Psoriasis
by Aleksandra Torbica & Giovanni Fattore & Fabio Ayala - 225-227 On the Use and Interpretation of Quantile Regression in Quality-of-Life Research
by Leonardo Koeser & Paul McCrone - 229-230 The Authors’ Reply to Koeser and McCrone: “On the Use and Interpretation of Quantile Regression in Quality-of-Life Research”
by Michela Tinelli & Anthony Scott & Janelle Seymour & Mandy Ryan & Christine Bond & Paul McNamee
January 2014, Volume 32, Issue 1
- 1-4 Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?
by Janine Til & Maarten IJzerman - 5-13 Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences
by Jeffrey Barletta & David Sclar - 15-27 Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
by Carl Asche & Stephen Hippler & Dean Eurich - 29-45 Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies
by Katelijne Vooren & Silvy Duranti & Alessandro Curto & Livio Garattini - 47-61 The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
by Gerardus Frederix & Johan Hasselt & Jan Schellens & Anke Hövels & Jan Raaijmakers & Alwin Huitema & Johan Severens - 63-74 Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare
by Fadia Shaya & Ian Breunig & Brian Seal & C. Mullins & Viktor Chirikov & Nader Hanna - 75-86 The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk
by Ana Bobinac & Job Exel & Frans Rutten & Werner Brouwer - 87-99 Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial
by Edward Wilson & Ludmila Shulgina & Anthony Cahn & Edwin Chilvers & Helen Parfrey & Allan Clark & Orion Twentyman & Andrew Wilson
December 2013, Volume 31, Issue 12
- 1087-1090 Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One
by Mattias Neyt & Patrice Chalon - 1091-1104 Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US
by Fred Hellinger - 1105-1119 How to Include Informal Care in Economic Evaluations
by Renske Hoefman & Job Exel & Werner Brouwer - 1121-1129 Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
by Sophie Beale & Rumona Dickson & Adrian Bagust & Michaela Blundell & Yenal Dundar & Angela Boland & Ernie Marshall & Ruth Plummer & Chris Proudlove - 1131-1154 The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review
by Michael Sonntag & Hans-Helmut König & Alexander Konnopka - 1155-1168 Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations
by Edwin Oberjé & Reina Kinderen & Silvia Evers & Cees Woerkum & Marijn Bruin - 1169-1183 A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare
by Esther Bekker-Grob & John Rose & Michiel Bliemer - 1185-1186 Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
by Anthony Bentley & Samantha Gillard & Michael Spino & John Connelly & Fernando Tricta
November 2013, Volume 31, Issue 11
- 959-970 Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations
by William Weintraub & Leonid Mandel & Sandra Weiss - 971-980 Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants
by Charalampos Kasmeridis & Stavros Apostolakis & Lars Ehlers & Lars Rasmussen & Giuseppe Boriani & Gregory Lip - 981-990 Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal
by Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson - 991-1003 Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment
by Bogdan Grigore & Jaime Peters & Christopher Hyde & Ken Stein - 1005-1030 Systematic Literature Review of the Costs of Pregnancy in the US
by Lynn Huynh & Mark McCoy & Amy Law & Kevin Tran & Senta Knuth & Patrick Lefebvre & Sean Sullivan & Mei Duh - 1031-1050 A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection
by Josephine Mauskopf - 1051-1061 Eliciting Preferences for Prioritizing Treatment of Rare Diseases: the Role of Opportunity Costs and Framing Effects
by Arna Desser & Jan Olsen & Sverre Grepperud - 1063-1082 The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries
by Zaheer-Ud-Din Babar & Charon Lessing & Cécile Mace & Karen Bissell
October 2013, Volume 31, Issue 10
- 841-852 Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal
by Ros Wade & Micah Rose & Aileen Neilson & Lisa Stirk & Rocio Rodriguez-Lopez & David Bowen & Dawn Craig & Nerys Woolacott - 853-861 Using the Stated Preference Technique for Eliciting Valuations: The Role of the Payment Vehicle
by Dorte Gyrd-Hansen - 863-876 The Road Not Taken: Transferability Issues in Multinational Trials
by Pepijn Vemer & Maureen Rutten-van Mölken - 877-892 Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review
by Susan Joy & Emily Little & Nisa Maruthur & Tanjala Purnell & John Bridges - 893-907 A Person Trade-Off Study to Estimate Age-Related Weights for Health Gains in Economic Evaluation
by Stavros Petrou & Ngianga-Bakwin Kandala & Angela Robinson & Rachel Baker - 909-918 Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
by Joris Kleintjens & Xiao Li & Steven Simoens & Vincent Thijs & Marnix Goethals & Ernst Rietzschel & Yumi Asukai & Ömer Saka & Thomas Evers & Petra Faes & Stefaan Vansieleghem & Mimi Ruyck - 919-931 Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients
by Antonio Blázquez-Pérez & Ramón San Miguel & Javier Mar - 933-957 Projecting Expenditure on Medicines in the UK NHS
by Phill O’Neill & Jorge Mestre-Ferrandiz & Ruth Puig-Peiro & Jon Sussex
September 2013, Volume 31, Issue 9
- 731-737 Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?
by Christopher McCabe & Richard Edlin & Peter Hall - 739-751 Protease Inhibitors for Hepatitis C: Economic Implications
by Stuart Turner & Jack Brown & Joseph Paladino - 753-766 The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue
by Alan Carlotto & Virginia Hogsett & Elyse Maiorini & Janet Razulis & Stephen Sonis - 767-780 Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions
by Denis Getsios & Jenő Marton & Nikhil Revankar & Alexandra Ward & Richard Willke & Dale Rublee & K. Ishak & James Xenakis - 781-797 Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making
by Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap - 799-806 Costs of Parkinson’s Disease in a Privately Insured Population
by Scott Johnson & Anna Kaltenboeck & Melissa Diener & Howard Birnbaum & ElizaBeth Grubb & Jane Castelli-Haley & Andrew Siderowf - 807-822 Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
by Anthony Bentley & Samantha Gillard & Michael Spino & John Connelly & Fernando Tricta - 823-839 Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
by Reginald Villacorta & Joel Hay & Andrew Messali
August 2013, Volume 31, Issue 8
- 635-641 Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities
by Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi - 643-652 Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations
by Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell - 653-661 Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal
by Jonathan Tosh & Rachel Archer & Sarah Davis & Matt Stevenson & John Stevens - 663-675 Overview of Parametric Survival Analysis for Health-Economic Applications
by K. Ishak & Noemi Kreif & Agnes Benedict & Noemi Muszbek - 677-691 Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies
by Victoria Brennan & Simon Dixon - 693-702 Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability
by Anthony Newall & Juan Dehollain & Prudence Creighton & Philippe Beutels & James Wood - 703-718 Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence
by Chantal Gils & Saskia Groot & William Redekop & Miriam Koopman & Cornelis Punt & Carin Uyl-de Groot - 719-730 A Choice That Matters?
by Pepijn Vemer & Maiwenn Al & Mark Oppe & Maureen Rutten-van Mölken
July 2013, Volume 31, Issue 7
- 551-562 Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal
by Rita Faria & Eldon Spackman & Jane Burch & Belen Corbacho & Derick Todd & Chris Pepper & Nerys Woolacott & Stephen Palmer - 589-604 A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
by Sonja Sorensen & Siyang Peng & Brigitta Monz & Carole Bradley-Kennedy & Anuraag Kansal - 605-621 The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia
by Annemieke Leunis & W. Redekop & Kees van Montfort & Bob Löwenberg & Carin Uyl-de Groot
June 2013, Volume 31, Issue 6
- 455-469 Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
by Joel Thompson & Amir Abdolahi & Katia Noyes - 471-478 Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
by Rachid Rafia & Emma Simpson & Matt Stevenson & Diana Papaioannou - 479-488 Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
by Ben Kearns & Myfanwy Lloyd Jones & Matt Stevenson & Chris Littlewood - 489-500 Disutility of Illness for Caregivers and Families: A Systematic Review of the Literature
by Eve Wittenberg & Lisa Prosser - 501-508 Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
by Fei-Li Zhao & Feng Xie & Hao Hu & Shu-Chuen Li - 509-518 Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes
by Tom Lung & Philip Clarke & Alison Hayes & Richard Stevens & Andrew Farmer - 519-531 Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome
by Anju Parthan & Kevin Leahy & Amy O’Sullivan & Olga Iakoubova & Lance Bare & James Devlin & Milton Weinstein - 533-535 A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’
by Przemysław Holko & Paweł Kawalec
May 2013, Volume 31, Issue 5
- 357-359 How Much Should the NHS Pay for a QALY?
by Alan Haycox - 361-367 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
by Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder - 369-373 Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al
by Pieter Baal & David Meltzer & Werner Brouwer - 375-376 The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”
by Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn - 377-391 Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
by Michael Sorich & Michael Wiese & Rebekah O’Shea & Brita Pekarsky - 393-401 Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing
by Simon Eckermann & Andrew Willan - 403-413 Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma
by Janette Greenhalgh & Adrian Bagust & Angela Boland & Michaela Blundell & James Oyee & Sophie Beale & Yenal Dundar & Juliet Hockenhull & Chris Proudlove & Patrick Chu - 415-425 Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
by Nigel Armstrong & Manuela Joore & Thea Asselt & Kate Misso & Nathan Manning & Florian Tomini & Jos Kleijnen & Rob Riemsma - 427-444 Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
by Kit Simpson & Pamela Pei & Jörgen Möller & Robert Baran & Birgitta Dietz & William Woodward & Kristen Migliaccio-Walle & J. Caro - 445-454 The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies
by Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten
April 2013, Volume 31, Issue 4
- 257-267 Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)
by SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang - 269-275 Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal
by E. Simpson & P. Fitzgerald & P. Evans & P. Tappenden & N. Kalita & J. Reckless & A. Bakhai - 277-288 A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events
by Fatiha Shabaruddin & Li-Chia Chen & Rachel Elliott & Katherine Payne - 289-304 Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention
by Stephanie Earnshaw & Andrew Brogan & Cheryl McDade - 305-315 Using a Discrete Choice Experiment to Elicit Time Trade-Off and Willingness-to-Pay Amounts for Influenza Health-Related Quality of Life at Different Ages
by Lisa Prosser & Katherine Payne & Donna Rusinak & Ping Shi & Mark Messonnier - 317-333 The Cost Effectiveness of Pharmacological Treatments for Generalized Anxiety Disorder
by Ifigeneia Mavranezouli & Nick Meader & John Cape & Tim Kendall - 335-343 Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?
by Albane Degrassat-Théas & Pascal Paubel & Olivier Parent de Curzon & Claude Pen & Martine Sinègre - 345-355 Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity
by Warren Linley & Dyfrig Hughes
March 2013, Volume 31, Issue 3
- 177-179 Improving Confidence in Observational Studies
by Eberechukwu Onukwugha - 181-183 What Evidence Is There for the Reimbursement of Personalised Medicine?
by Peter Hall & Christopher McCabe - 185-194 Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer
by Eldon Spackman & Stephen Rice & Gill Norman & Dong-Churl Suh & Alison Eastwood & Stephen Palmer - 195-213 Cost Effectiveness of Antiarrhythmic Medications in Patients Suffering from Atrial Fibrillation
by Bernd Brüggenjürgen & Stefan Kohler & Nadja Ezzat & Thomas Reinhold & Stefan Willich - 215-228 Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness
by Martin Frank & Thomas Mittendorf - 229-236 The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
by Jean Yong & Jaclyn Beca & Jeffrey Hoch - 237-250 The Economic Burden of Depression in Switzerland
by Yuki Tomonaga & Josef Haettenschwiler & Martin Hatzinger & Edith Holsboer-Trachsler & Michael Rufer & Urs Hepp & Thomas Szucs - 251-253 The State of Health Economic Research in South Africa
by Jeff Gow & Michael Strauss & Alan Whiteside - 255-256 The Authors’ Reply to Gow et al.: “The State of Health Economic Research in South Africa”
by Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza
February 2013, Volume 31, Issue 2
- 93-100 Cost-Effectiveness Acceptability Curves Revisited
by Maiwenn Al - 101-110 Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization
by Dawn Craig & Stephen Rice & Fiona Paton & David Fox & Nerys Woolacott - 111-123 Acknowledging Patient Heterogeneity in Economic Evaluation
by Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore - 125-136 A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination
by Thomas Szucs & Alena Pfeil - 137-149 When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?
by Louise Longworth & JiHee Youn & Laura Bojke & Stephen Palmer & Susan Griffin & Eldon Spackman & Karl Claxton - 151-161 Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling
by Yumi Asukai & Michael Baldwin & Tiago Fonseca & Alastair Gray & Laura Mungapen & David Price - 163-171 Valuing Benefits to Inform a Clinical Trial in Pharmacy
by Michela Tinelli & Mandy Ryan & Christine Bond & Anthony Scott - 173-174 Comparing Subsidized Access to Medicines Across Payer Systems
by Michael Wonder & Richard Milne - 175-176 The Authors’ Reply to Wonder and Milne: “Comparing Subsidized Access to Medicines Across Payer Systems”
by Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith
January 2013, Volume 31, Issue 1
- 1-10 Operationalizing Value-Based Pricing of Medicines
by Jon Sussex & Adrian Towse & Nancy Devlin - 11-14 Reference Pricing and Price Negotiations for Innovative New Drugs
by Afschin Gandjour - 15-24 Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma
by Mary Kilonzo & Jenni Hislop & Andrew Elders & Cynthia Fraser & Donald Bissett & Samuel McClinton & Graham Mowatt & Luke Vale - 25-48 A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice
by Lotte Steuten & Gijs Wetering & Karin Groothuis-Oudshoorn & Valesca Retèl - 49-61 The Humanistic and Economic Burden of Systemic Lupus Erythematosus
by Rachel Meacock & Nicola Dale & Mark Harrison - 63-75 Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B
by María Buti & Itziar Oyagüez & Virginia Lozano & Miguel Casado